Filing Flows › BridgeBio Pharma (BBIO) › How it makes money
How BridgeBio Pharma (BBIO) makes money
BridgeBio Pharma (BBIO) made $353M of revenue in the third quarter 2026 (Q3 2026), +193% from a year earlier. Net product revenue brought in $253M (72%); License and services revenue brought in $79.3M (22%); Royalty revenue brought in $20.5M (6%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product revenue | $253M | 71.7% | +14% | +134% |
| License and services revenue | $79.3M | 22.5% | 14× | +854% |
| Royalty revenue | $20.5M | 5.8% | +33% | +379% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $353M | 100.0% |
| Income tax | $1.2M | 0.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $353M | +193% |
| Q2 2026 | $244M | +120% |
| Q1 2026 | $195M | +67% |
| Q4 2025 | $154M | 26× |
| Q3 2025 | $121M | 44× |
| Q2 2025 | $111M | 51× |
| Q1 2025 | $117M | -45% |
From BridgeBio Pharma's 10-Q filed Oct 29, 2026 (on EDGAR).
Questions
How does BridgeBio Pharma make money?
BridgeBio Pharma (BBIO) made $353M of revenue in the third quarter 2026 (Q3 2026), +193% from a year earlier. Net product revenue brought in $253M (72%); License and services revenue brought in $79.3M (22%); Royalty revenue brought in $20.5M (6%).
What is BridgeBio Pharma's biggest business?
Net product revenue: $253M in the third quarter 2026, 72% of revenue, +134% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.